p53 is a persistent and predictive marker in advanced ovarian carcinomas: Multivariate analysis including comparison with KI67 immunoreactivity

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 9, 1997, Pages 496-501

  Röhlke, Peter ^a   Milde Langosch, Karin ^a   Weyland, Christine ^a   Pichlmeier, Uwe ^a   Jonat, Walter ^b   Löning, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Ki67; Metastasis Prognosis; Ovarian carcinoma; P53

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADULT; AGED; CARCINOMA; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030881036     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050094     Document Type: Article

References (19)

1. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G (1993) p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 24:1175-1179
2. Eccles DM, Cranston G, Steel CM, Nakamura Y, Leonard RCF (1990) Allele losses on chromosome 17 in human epithelial ovarian cancer. Oncogene 5:1599-1601
3. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11:1217-1228
4. Gerdes J (1990) Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1:99-206
5. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA, Roche PC (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12:64-69
6. Isola J, Kallioniemi O-P, Korte J-M, Wahlström T, Aine R, Helle M, Helin H (1990) Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol 162:295-301
7. Kappes S, Milde-Langosch K, Kressin P, Passlack B, Dockhorn-Dworniczak B, Röhlke P, Löning T (1995) p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer 64:52-59
8. Kiene P, Milde-Langosch K, Runkel M, Schulz K, Löning T (1992) A simple and rapid technique to process formalin-fixed, paraffin-embedded tissues for the detection of viruses by the polymerase chain reaction. Virchows Arch [A] 420:269-273
9. Klemi P-J, Pylkkänen L, Kiilholma P, Kurvinen K, Joensuu H (1995) P53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76:1201-1208
10. Kupryjanczuk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90:4961-4965
11. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis EP (1995) Mutant p53 overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75:1327-1338
12. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Löning T (1995) Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer 63:639-645
13. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly K, Parkin DE, Haites NE (1993) p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 53:2128-2132
14. Pieretti M, Powell DE, Gallion HH, Conway PS, Case EA, Turker MS (1995) Hypermethylation at a chromosome 17 "hot spot" is a common event in ovarian cancer. Hum Pathol 26:398-401
15. Reles A, Schmider A, Press MF, Schönborn I, Friedmann W, Huber-Schumacher S, Strohmeyer T, Lichtenegger W (1996) Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol 122:489-494
16. Righetti SC, Della Torre G, Pilotti S, Ménard S, Ottone F, Colnaghi MI, Pietotti MA, Lavarino C, Cornarotti M, Oriana S, Böhm S, Bresciani GL, Spatti G, Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56:689-693
17. Selivanova G, Wiman KG (1995) P53: a cell cycle regulator activated by DNA damage. Adv Cancer Res 66:143-180
18. Scholz RB, Milde-Langosch K, Jung R, Schlechte H, Kubisch H, Wagener C, Löning T (1993) Rapid screening for Tp53 mutations by temperature gradient gel electrophoresis: a comparison with SSCP analysis. Hum Mol Genet 2:2155-2158
19. Wu GS, El-Deiry WS (1996) p53 and chemosensitivity. Nat Med 2:255-256